Literature DB >> 6652907

Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia.

R Berger, H van Faassen, G P Smith.   

Abstract

Experiments are described on the effects of succinylacetone and fumarylacetoacetate on delta-aminolevulinic acid dehydratase, methionine adenosyltransferase and p-OH-phenylpyruvate dioxygenase. delta-Aminolevulinic acid dehydratase from human erythrocytes is inhibited non-competitively by succinylacetone (Ki 0.03 mumol/l) and by fumarylacetoacetate (Ki 0.06 mumol/l). The inhibition by succinylacetone is not prevented by dithiothreitol, but the inhibition by fumarylacetoacetate is not observed if dithiothreitol is present. Methionine adenosyltransferase, partially purified from rabbit liver, is not inhibited by succinylacetone but is inhibited by fumarylacetoacetate: 69% inhibition is observed at 1 mmol/l. Human liver p-OH-phenylpyruvate dioxygenase is not inhibited by succinylacetone or fumarylacetoacetate. It is concluded that secondary enzyme deficiencies observed in hereditary tyrosinemia (delta-aminolevulinic acid dehydratase, methionine adenosyl transferase) are the result of inhibition by succinylacetone and fumarylacetoacetate, accumulating as a result of a primary deficiency of fumarylacetoacetase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652907     DOI: 10.1016/0009-8981(83)90191-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  11 in total

1.  Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I.

Authors:  N André; B Roquelaure; V Jubin; C Ovaert
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.

Authors:  J L Aponte; G A Sega; L J Hauser; M S Dhar; C M Withrow; D A Carpenter; E M Rinchik; C T Culiat; D K Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

3.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

4.  Prenatal diagnosis of tyrosinaemia type I by use of stable isotope dilution mass spectrometry.

Authors:  C Jakobs; E A Kvittingen; R Berger; A Haagen; W Kleijer; M Niermeijer
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

5.  Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Authors:  Yue Tang; Yuanyuan Kong
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

Review 6.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.

Authors:  H Schierbeek; G J Beukeveld; H van Faassen; F J van Spronsen; K Bijsterveld; E E Venekamp-Hoolsema; B G Wolthers; G P Smit
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

8.  Clinical features and diagnostic approach in type I tyrosinaemia in an infant with cytomegaly virus infection and bacterial sepsis.

Authors:  M Wabitsch; F Pohlandt; D Leupold; R Berger; E Mönch; E Heinze; W Teller
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

Review 9.  Tyrosinaemia type I--an update.

Authors:  E A Kvittingen
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

10.  Tyrosinaemia type 1 and glutathione synthetase deficiency: two disorders with reduced hepatic thiol group concentrations and a liver 4-fumarylacetoacetate hydrolase deficiency.

Authors:  A J Lloyd; R G Gray; A Green
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.